Ultracet®
Tramadol / Acetaminophen · oral tablet
Analgesics
Approved uses
Acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate (non-ocular; the only approved indication)
2 tablets (tramadol hydrochloride 37.5 mg with acetaminophen 325 mg) every 4 to 6 hours as needed, maximum 8 tablets per day, for five days or less; creatinine clearance under 30 mL/min, maximum 2 tablets every 12 hours
Contraindications
- Children younger than 12 years
- Postoperative management in children younger than 18 years following tonsillectomy or adenoidectomy
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Previous hypersensitivity to tramadol, acetaminophen, any other component of the product, or opioids
- Concurrent monoamine oxidase inhibitor use, or MAOI use within the last 14 days
Tablets: tramadol hydrochloride 37.5 mg with acetaminophen 325 mg, bottles of 100 tablets, packages of 100 unit doses
Combination of tramadol, a mu-opioid agonist that also weakly inhibits norepinephrine and serotonin reuptake, with acetaminophen, a non-opioid non-salicylate analgesic whose analgesic site is undetermined and thought to be primarily central. Opioid activity comes from both low affinity binding of the parent compound and higher affinity binding of the metabolite M1 to mu-opioid receptors.
Warnings & Precautions
- Addiction, abuse, and misuse: ULTRACET contains tramadol, a Schedule IV controlled substance, and exposes users to the risks of addiction, abuse, and misuse, which can lead to overdose and death. Addiction can occur at recommended dosages. Assess each patient's risk before prescribing and monitor all patients regularly for these behaviors and conditions. This is a boxed warning.
- Opioid analgesic REMS: FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesics, under which drug companies must make REMS-compliant education programs available to healthcare providers. Providers are strongly encouraged to complete such a program and to counsel patients and caregivers on safe use, serious risks, storage, and disposal with every prescription. This is a boxed warning.
- Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur, and the risk is greatest during initiation of therapy or after a dosage increase. Monitor closely, especially within the first 24 to 72 hours of therapy and after dosage increases. Opioids can also cause central sleep apnea and sleep-related hypoxemia. Discuss naloxone availability with the patient and caregiver when initiating and renewing treatment. This is a boxed warning.
- Accidental ingestion: Accidental ingestion of even one dose of ULTRACET, especially by children, can result in a fatal overdose of tramadol. This is a boxed warning.
- Life-threatening respiratory depression in children: Life-threatening respiratory depression and death have occurred in children who received tramadol, some after tonsillectomy and/or adenoidectomy; at least one child had evidence of being a CYP2D6 ultra-rapid metabolizer. Avoid use in adolescents 12 to 18 years of age with other risk factors, such as obstructive sleep apnea or obesity, unless the benefits outweigh the risks. Ultra-rapid metabolizers should not use ULTRACET. This is a boxed warning.
- Neonatal opioid withdrawal syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise her of the risk and ensure that appropriate treatment will be available. This is a boxed warning.
- Risks of interactions with drugs affecting cytochrome P450: The effects of starting or stopping CYP3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors on tramadol and M1 levels are complex. Higher tramadol levels may raise the risk of seizures and serotonin syndrome, higher M1 levels after stopping a 2D6 inhibitor may cause potentially fatal respiratory depression, and lower levels may cause opioid withdrawal in some patients. This is a boxed warning.
- Hepatotoxicity: Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most cases involve doses above 4,000 milligrams per day and often more than one acetaminophen-containing product, and the risk is higher with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen. Do not use with other acetaminophen-containing products. This is a boxed warning.
- Profound sedation, respiratory depression, coma, and death: These may result from concomitant use with benzodiazepines or other CNS depressants, including alcohol. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate, limit dosages and durations to the minimum required, and follow patients for signs and symptoms of respiratory depression and sedation. This is a boxed warning.
- Serotonin syndrome: Serotonin syndrome, a potentially life-threatening condition, can occur with tramadol alone or with serotonergic drugs such as SSRIs, SNRIs, TCAs, triptans, cyclobenzaprine, MAO inhibitors, linezolid, or intravenous methylene blue, and may occur within the recommended dosage range. Discontinue ULTRACET if serotonin syndrome is suspected.
- Seizures: Seizures have been reported within the recommended dosage range, and spontaneous postmarketing reports indicate that seizure risk is increased above it. Seizure risk is also increased with SSRIs, SNRIs, TCAs, other opioids, MAO inhibitors, or neuroleptics. Risk may also increase in patients with epilepsy, a history of seizures, or a recognized risk for seizure such as head trauma or alcohol and drug withdrawal. In tramadol overdose, naloxone administration may increase the risk of seizure.
- Suicide risk: Do not prescribe ULTRACET for patients who are suicidal or addiction-prone, and consider non-narcotic analgesics in patients who are suicidal or depressed. Prescribe with caution for patients with a history of misuse, those taking CNS-active drugs or alcohol in excess, and those with emotional disturbance or depression.
- Adrenal insufficiency: Cases have been reported with opioid use, more often after more than one month of use. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If it is diagnosed, treat with physiologic replacement doses of corticosteroids and wean the patient off the opioid.
- Decreased respiratory drive including apnea: Patients with significant chronic obstructive pulmonary disease or cor pulmonale, substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk, even at recommended dosages. Life-threatening respiratory depression is more likely in elderly, cachectic, or debilitated patients. Monitor such patients closely, particularly when initiating and titrating, or consider non-opioid analgesics.
- Severe hypotension: ULTRACET may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (such as phenothiazines or general anesthetics). Monitor these patients for signs of hypotension after initiating or titrating the dosage, and avoid use in patients with circulatory shock.
- Increased intracranial pressure: In patients with increased intracranial pressure or brain tumors, ULTRACET may reduce respiratory drive, and the resulting CO2 retention can further increase intracranial pressure. Monitor for sedation and respiratory depression, particularly when initiating therapy. Opioids may also obscure the clinical course in a patient with a head injury. Avoid use in patients with impaired consciousness or coma.
- Serious skin reactions: Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be fatal. Inform patients of the signs, and discontinue at the first appearance of skin rash or any other sign of hypersensitivity.
- Acute angle closure: Mydriasis is a postmarketing eye disorder on this label. Two single case reports describe bilateral acute angle closure after tramadol. In the subcutaneous case, the patient was a 42-year-old healthy man with unremarkable past medical and ocular history. In the oral case, the authors judged that significant hyperopia and very short axial lengths likely played a dominant role and that oral tramadol may have acted as a permissive factor rather than as a sole causative agent.
- Spasm of the sphincter of Oddi: The tramadol in ULTRACET may cause spasm of the sphincter of Oddi, and opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
- Anaphylaxis and other hypersensitivity reactions: Serious and rarely fatal anaphylactic reactions have been reported with tramadol, often after the first dose, and anaphylaxis has also been reported with acetaminophen. Do not give ULTRACET to patients with a history of anaphylactoid reactions to tramadol and other opioids or with acetaminophen allergy. If a reaction occurs, stop ULTRACET immediately, discontinue it permanently, and do not rechallenge with any formulation of tramadol.
- Withdrawal: Do not abruptly discontinue ULTRACET in a patient physically dependent on opioids, and gradually taper the dosage, because rapid discontinuation has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Avoid mixed agonist/antagonist (such as pentazocine, nalbuphine, and butorphanol) or partial agonist (such as buprenorphine) analgesics, which may reduce the analgesic effect or precipitate withdrawal symptoms.
- Impaired mental or physical abilities: ULTRACET may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of ULTRACET and know how they will react to it.
- Hyponatremia: Hyponatremia (serum sodium below 135 mmol/L) has been reported with tramadol, and many cases are severe (sodium level below 120 mmol/L). Most cases occurred in females over the age of 65 and within the first week of therapy, and some resulted from SIADH. Monitor for signs such as confusion and disorientation, especially at initiation, and if signs are present, start appropriate treatment and discontinue ULTRACET.
- Hypoglycemia: Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization, and in most cases patients had predisposing risk factors such as diabetes. If hypoglycemia is suspected, monitor blood glucose levels and consider drug discontinuation as appropriate.
Common Side Effects
The most common adverse events (3.0% or more) over five days of use in clinical trials (N=142) were constipation (6%), somnolence (6%), sweating increased (4%), diarrhea (3%), nausea (3%), anorexia (3%) and dizziness (3%), and dry mouth, insomnia, pruritus and prostatic disorder in males each occurred in 2%. Abnormal vision occurred in less than 1% in clinical trials, and miosis and mydriasis have been reported postmarketing. Serious adverse reactions include respiratory depression, seizures, serotonin syndrome, anaphylaxis, acute liver failure and adrenal insufficiency, and postmarketing reports include QT prolongation and/or torsade de pointes, hyponatremia and/or SIADH, hypoglycemia and androgen deficiency with chronic use of opioids.
Pregnancy: Available data with ULTRACET in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage, and based on animal data, pregnant women should be advised of the potential risk to a fetus. Prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome, and neonatal seizures, neonatal withdrawal syndrome, fetal death and stillbirth have been reported with tramadol during postmarketing. ULTRACET is not recommended during or immediately prior to labor.
Lactation: Breastfeeding is not recommended during treatment because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant. Tramadol and its more potent metabolite M1 are present in human milk, and mothers who are ultra-rapid metabolizers may have higher M1 levels in breast milk that can be dangerous to their breastfed infants.
Safety and effectiveness not established; contraindicated under 12 years and for post-tonsillectomy or adenoidectomy pain under 18 years; avoid in adolescents 12 to 18 years with other risk factors for respiratory depression unless the benefits outweigh the risks.